# Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients

> **NCT04488926** · PHASE4 · COMPLETED · sponsor: **Epitech Group SpA** · enrollment: 21 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DIETARY_SUPPLEMENT:** micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules
- **OTHER:** Placebo microgranules 1800mg
- **DRUG:** Standard Therapy
- **DRUG:** Rescue Drug

## Key facts

- **NCT ID:** NCT04488926
- **Lead sponsor:** Epitech Group SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2022-05-02
- **Final completion:** 2022-05-02
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04488926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04488926, "Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04488926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*